The long-term antipsychotic treatment of schizophrenia: A selective review of clinical guidelines and clinical case examples

被引:18
|
作者
Gaebel, Wolfgang [1 ,2 ]
Stricker, Johannes [1 ,2 ]
Riesbeck, Mathias [1 ]
机构
[1] Heinrich Heine Univ, Med Fac, LVR Klinikum Dusseldorf, Dept Psychiat & Psychotherapy, Dusseldorf, Germany
[2] WHO Collaborating Ctr Qual Assurance & Empowermen, Dusseldorf, Germany
关键词
Schizophrenia; Guideline; Antipsychotic; Long-term; Maintenance; Pharmacotherapy; GERMAN RESEARCH NETWORK; RANDOMIZED CONTROLLED-TRIAL; RELAPSE FOLLOWING DISCONTINUATION; 1ST-EPISODE SCHIZOPHRENIA; 1ST EPISODE; MAINTENANCE TREATMENT; MEDICATION DISCONTINUATION; TREATMENT STRATEGIES; FOLLOW-UP; PREDICTORS;
D O I
10.1016/j.schres.2019.10.049
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
There is a long-lasting debate regarding the long-term antipsychotic treatment of schizophrenia. The most frequently advocated strategy is continued antipsychotic maintenance treatment (i.e., continuous treatment with a constant dose of antipsychotic medication after symptom remission). Yet, because of the potential side effects of continued antipsychotic medication, other treatment strategies such as targeted intermittent treatment (i.e., stepwise drug discontinuation and early drug intervention in case of prodromal symptoms or early warning signs) have been discussed. In this manuscript, we review recommendations regarding the long-term antipsychotic treatment of schizophrenia from six evidence-based clinical guidelines. In line with the current state of research, all six clinical guidelines recommend continued antipsychotic maintenance treatment. Recommendations regarding other aspects of long-term antipsychotic treatment (e.g., the dosage of antipsychotic medication for long-term treatment, the minimum duration of antipsychotic long-term treatment, and discontinuation strategies) are more vague and heterogeneous. Additionally, we provide clinical case examples to illustrate different course types of patients exposed to targeted intermittent treatment. Finally, we discuss gaps in current clinical guidelines and future research avenues in antipsychotic maintenance treatment. (C) 2019 Elsevier B.V. All rights reserved.
引用
收藏
页码:4 / 14
页数:11
相关论文
共 50 条
  • [1] The revised DGPPN and APA schizophrenia guidelines: Guideline quality and recommendations for long-term antipsychotic treatment
    Gaebel, Wolfgang
    Stricker, Johannes
    Hasan, Alkomiet
    Falkai, Peter
    McIntyre, John S.
    Kerst, Ariane
    SCHIZOPHRENIA RESEARCH, 2021, 229 : 137 - 139
  • [2] The Long-Term Effects of Antipsychotic Medication on Clinical Course in Schizophrenia
    Goff, Donald C.
    Falkai, Peter
    Fleischhacker, W. Wolfgang
    Girgis, Ragy R.
    Kahn, Rene M.
    Uchida, Hiroyuki
    Zhao, Jingping
    Lieberman, Jeffrey A.
    AMERICAN JOURNAL OF PSYCHIATRY, 2017, 174 (09) : 840 - 849
  • [3] Antipsychotic treatment in the maintenance phase of schizophrenia: An updated systematic review of the guidelines and algorithms
    Shimomura, Yutaro
    Kikuchi, Yuhei
    Suzuki, Takefumi
    Uchida, Hiroyuki
    Mimura, Masaru
    Takeuchi, Hiroyoshi
    SCHIZOPHRENIA RESEARCH, 2020, 215 : 8 - 16
  • [4] Long-term outcomes of antipsychotic treatment in patients with first-episode schizophrenia: a systematic review
    Karson, Craig
    Duffy, Ruth A.
    Eramo, Anna
    Nylander, Anna-Greta
    Offord, Steve J.
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2016, 12 : 57 - 67
  • [5] Long-term combination antipsychotic treatment in VA patients with schizophrenia
    Kreyenbuhl, Julie
    Valenstein, Marcia
    McCarthy, John F.
    Ganoczy, Dara
    Blow, Frederic C.
    SCHIZOPHRENIA RESEARCH, 2006, 84 (01) : 90 - 99
  • [6] Surgically implantable long-term antipsychotic delivery systems for the treatment of schizophrenia
    Siegel, SJ
    Winey, KI
    Gur, RE
    Lenox, RH
    Bilker, WB
    Ikeda, D
    Gandhi, N
    Zhang, WX
    NEUROPSYCHOPHARMACOLOGY, 2002, 26 (06) : 817 - 823
  • [7] Surgically Implantable Long-term Antipsychotic Delivery Systems for the Treatment of Schizophrenia
    Steven J Siegel
    Karen I Winey
    Raquel E Gur
    Robert H Lenox
    Warren B Bilker
    Debbie Ikeda
    Neel Gandhi
    Wen-Xiao Zhang
    Neuropsychopharmacology, 2002, 26 : 817 - 823
  • [8] What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?
    Correll, Christoph U.
    Rubio, Jose M.
    Kane, John M.
    WORLD PSYCHIATRY, 2018, 17 (02) : 149 - 160
  • [9] Long-term Continuity of Antipsychotic Treatment for Schizophrenia: A Nationwide Study
    Rubio, Jose M.
    Taipale, Heidi
    Tanskanen, Antti
    Correll, Christoph U.
    Kane, John M.
    Tiihonen, Jari
    SCHIZOPHRENIA BULLETIN, 2021, 47 (06) : 1611 - 1620
  • [10] Long-term treatment of bipolar disorder type I: A systematic and critical review of clinical guidelines with derived practice algorithms
    Verdolini, Norma
    Hidalgo-Mazzei, Diego
    Del Matto, Laura
    Muscas, Michele
    Pacchiarotti, Isabella
    Murru, Andrea
    Samalin, Ludovic
    Aedo, Alberto
    Tohen, Mauricio
    Grunze, Heinz
    Young, Allan H.
    Carvalho, Andre F.
    Vieta, Eduard
    BIPOLAR DISORDERS, 2021, 23 (04) : 324 - 340